Search & Analyze

Biocon Ltd.

HealthcarePharmaceuticals & Drugs

www.biocon.com BSE: 532523NSE: BIOCON

₹393.50BSE0.82%

07 Sep, 4:01 PM

₹393.50

₹64.13K Cr

129.47

1.89

1.35%

₹397.25

₹388.70

₹447.00

₹337.20

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,899.80	37.69	4,55,825.66	0.84	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,305.00	84.45	2,47,018.51	0.32	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,913.00	85.68	1,86,874.73	0.77	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,155.00	25.53	1,15,211.69	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,395.95	33.46	1,12,773.00	0.93	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,868.25	92.32	1,00,943.83	0.11	362.07	123.94%	2,026.31	29.10%	18.20
LUPIN LTD. LUPIN	2,105.00	17.41	96,254.46	0.86	1,416.98	16.01%	8,276.89	32.04%	28.86
Biocon Ltd. BIOCON	393.50	129.47	64,128.46	0.13	136.80	53.36%	4,336.00	10.00%	3.26

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	3,432.90	3,590.40	3,821.40	4,417.00	3,941.90	4,295.50	4,173.00	4,516.60	4,336.00
Expenses	2,812.50	2,905.00	3,069.60	3,338.80	3,175.80	3,460.10	3,339.50	3,496.30	3,488.80
	620.40	685.40	751.80	1,078.20	766.10	835.40	833.50	1,020.30	847.20
	18.07%	19.09%	19.67%	24.41%	19.43%	19.45%	19.97%	22.59%	19.54%
	1,166.50	58.50	52.90	57.30	62.50	81.10	-176.10	-27.90	41.00
Interest	236.00	225.60	223.40	212.40	276.70	272.20	209.90	231.50	213.20
	405.40	419.90	425.40	436.30	455.00	473.00	515.30	513.40	547.40
	1,145.50	98.40	155.90	486.80	96.90	171.30	-67.80	247.50	127.60
	24.77%	72.46%	47.98%	5.63%	7.95%	22.48%	23.60%	19.76%	-7.21%
	659.70	-16.00	25.10	344.50	31.40	84.50	143.80	125.90	141.10
	5.49	-0.13	0.21	2.87	0.23	0.63	1.08	0.78	0.87

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	8,208.20	11,276.70	14,929.00	15,338.80	17,030.40
	8,184.00	11,174.20	14,755.70	15,261.70	16,927.00
EXPENDITURE :
Increase/Decrease in Stock	-256.60	-154.10	-856.70	294.20	-949.50
Raw Material Consumed	2,975.00	3,817.20	5,754.60	4,903.30	6,640.20
Power & Fuel Cost	316.40	414.80	388.90	377.90	426.40
Employee Cost	1,880.10	2,181.00	2,664.10	3,144.40	3,508.00
Other Manufacturing Expenses	1,243.50	1,917.20	2,376.90	1,655.90	1,796.20
General and Administration Expenses	181.50	359.60	806.00	948.10	1,065.90
Selling and Distribution Expenses	243.80	221.60	296.60	649.90	698.80
Miscellaneous Expenses	107.70	297.40	128.60	269.30	399.40
	6,691.40	9,054.70	11,559.00	12,243.00	13,585.40
Operating Profit (Excl OI)	1,492.60	2,119.50	3,196.70	3,018.70	3,341.60
	690.30	768.10	967.50	1,355.80	456.20
	2,182.90	2,887.60	4,164.20	4,374.50	3,797.80
Interest	67.60	419.00	974.40	897.40	990.30
PBDT	2,115.30	2,468.60	3,189.80	3,477.10	2,807.50
	814.20	1,113.10	1,568.80	1,687.00	1,956.70
Profit Before Taxation & Exceptional Items	1,301.10	1,355.50	1,621.00	1,790.10	850.80
Exceptional Income / Expenses	-111.10	-291.40	-11.60	96.50	-402.90
	983.10	897.10	1,525.20	1,886.60	447.90
Provision for Tax	211.50	254.10	227.40	457.20	79.10
	771.60	643.00	1,297.80	1,429.40	368.80
Extra items				0.00	0.00
Minority Interest	-123.20	-180.30	-275.30	-416.10	16.80
Consolidated Net Profit	648.40	462.70	1,022.50	1,013.30	385.60
Profit Balance B/F	6,235.80	6,827.30	16,085.90	17,602.80	18,959.10
Appropriations	6,884.20	7,290.00	17,108.40	18,616.10	19,344.70
Equity Dividend %	10.00%	30.00%	10.00%	10.00%	10.00%
	5.40	3.85	8.52	8.44	2.38
Adjusted EPS	5.40	3.85	8.52	8.44	2.38

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	600.30	600.30	600.30	600.30	810.50
Share Warrants & Outstandings	204.10	274.00	320.10	424.90	514.30
Total Reserves	7,628.10	16,992.60	18,863.30	20,618.80	32,707.00
Reserve excluding Revaluation Reserve	7,627.20	16,991.70	18,862.40	20,617.90	32,706.10
Revaluation reserve	0.90	0.90	0.90	0.90	0.90
	8,432.50	17,866.90	19,783.70	21,644.00	34,031.80
Minority Interest	1,037.50	4,621.90	5,491.10	6,068.50	2,589.70
Secured Loans	2,574.30	13,692.30	11,267.70	10,502.50	10,476.30
Unsecured Loans	1,424.20	1,598.20	1,664.70	1,902.90	270.00
Deferred Tax Assets / Liabilities	-241.00	80.80	74.20	100.00	-313.90
Other Long Term Liabilities	2,953.50	5,144.50	1,875.60	3,727.10	1,641.60
Long Term Provisions	91.70	226.50	237.60	260.80	330.30
Total Non-Current Liabilities	6,802.70	20,742.30	15,119.80	16,493.30	12,404.30
Trade Payables	1,608.50	3,842.00	6,272.00	6,548.70	6,772.10
Other Current Liabilities	1,031.20	1,814.90	6,481.20	3,965.70	3,059.30
Short Term Borrowings	896.00	2,480.20	2,149.20	3,454.70	3,566.30
Short Term Provisions	292.30	373.60	456.40	364.70	671.50
Total Current Liabilities	3,828.00	8,510.70	15,358.80	14,333.80	14,069.20
Total Liabilities	20,100.70	51,741.80	55,753.40	58,539.60	63,095.00
Gross Block	11,233.00	35,321.40	37,930.10	40,804.30	48,079.20
Less: Accumulated Depreciation	4,664.00	5,853.70	7,286.50	8,841.00	11,593.30
Net Block	6,569.00	29,467.70	30,643.60	31,963.30	36,485.90
Capital Work in Progress	3,420.30	2,587.50	3,985.20	4,101.70	4,612.70
Non Current Investments	370.20	742.30	684.10	679.70	1,089.30
Long Term Investment	370.20	742.30	684.10	679.70	1,089.30
Long Term Loans & Advances	483.80	683.20	892.50	870.80	973.80
Other Non Current Assets	185.00	1,197.60	360.70	231.20	379.50
Total Non-Current Assets	11,718.40	39,407.80	40,574.20	42,253.40	45,915.20
Currents Investments	1,217.70	1,326.50	315.60	447.30	689.80
Inventories	2,298.20	4,243.70	4,943.90	4,931.10	6,085.70
Sundry Debtors	2,058.20	3,573.20	6,230.60	5,487.90	5,986.80
Cash and Bank	1,747.50	2,400.10	2,258.70	4,120.20	3,193.60
Other Current Assets	660.20	334.10	334.40	382.70	419.20
Short Term Loans and Advances	400.50	456.40	1,096.00	917.00	804.70
Total Current Assets	8,382.30	12,334.00	15,179.20	16,286.20	17,179.80
Net Current Assets (Including Current Investments)	4,554.30	3,823.30	-179.60	1,952.40	3,110.60
Total Assets	20,100.70	51,741.80	55,753.40	58,539.60	63,095.00
Contingent Liabilities	844.40	947.80	1,135.60	1,176.10	928.40
Total Debt	4,904.00	17,770.70	15,729.60	17,755.50	14,824.70
	68.53	146.53	162.11	176.73	206.77
Adjusted Book Value	68.53	146.53	162.11	176.73	206.77

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	983.10	897.10	1,525.20	1,886.60	447.90
Adjustment	1,245.00	1,685.00	2,356.20	1,711.20	2,920.90
Changes In working Capital	-789.50	-501.00	-635.20	923.00	-1,132.20
Cash Flow after changes in Working Capital	1,438.60	2,081.10	3,246.20	4,520.80	2,236.60
Cash Flow from Operating Activities	1,176.60	1,852.50	2,953.90	4,061.20	1,994.00
Cash Flow from Investing Activities	-1,699.10	-14,281.80	-1,004.50	-234.10	-2,082.10
Cash Flow from Financing Activitie	242.10	13,048.70	-2,332.70	-1,854.00	-923.60
Net Cash Inflow / Outflow	-280.40	619.40	-383.30	1,973.10	-1,011.70
Opening Cash & Cash Equivalents	897.00	653.70	1,299.90	919.50	2,923.80
Cash & Cash Equivalent on Amalgamation / Take over / Merger	33.80
Effect of Foreign Exchange Fluctuations	3.30	21.70	2.90	31.20	199.40
Closing Cash & Cash Equivalent	653.70	1,294.80	919.50	2,923.80	2,111.50

Ratios

Valuation

129.47

1.89

19.66

3.74

3.04

208.53

Profitability

1.35

3.26

0.61

19.62

2.17

Leverage & Liquidity

0.44

1.22

1.45

Returns

0.13

0.28

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	60.64	60.64	60.64	60.64	54.45	54.45	54.45	44.91	44.68
	20.20	20.37	21.02	21.38	28.86	28.71	29.10	31.59	31.52
	19.17	18.99	18.34	17.97	16.68	16.83	16.45	23.49	23.80
	39.36	39.36	39.36	39.36	45.55	45.55	45.55	55.09	55.32
No. of Shareholders	4,43,513	4,39,503	4,27,705	4,24,297	4,28,131	4,13,191	3,94,279	3,86,593	3,92,833

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-07-28	Board Meeting	Quarterly Results
2026-07-15	AGM
2026-05-08	Ex Dividend	Rs.0.5000 per share(10%)Final Dividend	2026-07-03	2026-07-03

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Biocon Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

17 members across the board and senior leadership

Rajesh Shanoy

Company Secretary & Compliance Officer

—

Kiran Mazumdar-Shaw

Chairperson

₹5.50 Cr

Mar '26

Shreehas Pradeep Tambe

Managing Director & CEO

—

Ravi Rasendra Mazumdar

Non Independent & Non Executive Director

₹79.00 L

Mar '26

Eric Vivek Mazumdar

Non Independent & Non Executive Director

₹66.80 L

Mar '26

Naina Lal Kidwai

Non Executive Independent Director

₹1.02 Cr

Mar '26

Bobby Kanubhai Parikh

Non Executive Independent Director

₹83.30 L

Mar '25

Rekha Mehrotra Menon

Non Executive Independent Director

₹79.90 L

Mar '26

Rajiv Malik

Independent Director

—

Nicholas Robert Haggar

Non Executive Independent Director

₹80.50 L

Mar '26

Atul Dhawan

Non Executive Independent Director

₹74.00 L

Mar '26

Rajesh Umakant Shanoy

Company Secretary and Compliance Officer

—

Daniel Bradbury

Independent Director

—

Arun Suresh Chandavarkar

Independent Director

—

Nivruti Rai

Independent Director

—

Thomas Jason Roberts

Non Independent & Non Executive Director

—

Peter Baron Piot

Independent Director

—

BIOCON Latest News

News

10 of 10 articles

COMPANY25 Aug 2026 · 10:47

Biocon’s arm secures marketing approval for pegfilgrastim biosimilar in Japan

This approval further strengthens the company’s portfolio of biosimilar products in Japan

EQUITY25 Aug 2026 · 09:23

Biocon informs about company statement

EQUITY18 Aug 2026 · 11:39

Biocon informs about disclosure

EQUITY6 Aug 2026 · 11:37

Biocon surges on reporting over 4-fold jump in Q1 consolidated net profit

The total consolidated income of the company has increased by 9.17% at Rs 4,390.50 crore for Q1FY27

COMPANY6 Aug 2026 · 10:50

Biocon reports over 4-fold jump in Q1 consolidated net profit

The total consolidated income of the company has increased by 9.17% at Rs 4,390.50 crore for Q1FY27

EQUITY6 Aug 2026 · 09:56

Biocon informs about earnings call

EQUITY3 Aug 2026 · 11:35

Biocon moves up on launching Yesafili in United States

Yesafili (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg

COMPANY3 Aug 2026 · 09:42

Biocon launches Yesafili in United States

Yesafili (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg

EQUITY3 Aug 2026 · 09:31

Biocon informs about newspaper advertisement

COMPANY29 Jul 2026 · 14:10

Biocon’s arm secures Health Canada’s nod for Yesintek (ustekinumab) Autoinjector Pen

This approval further strengthens the company’s portfolio of immunology products in Canada

BIOCON

₹393.50

-0.82%